Physician profile
Anna M Solum
NPI 1073585618
$29,138.58
in general payments reported to CMS, 2019-2025
27 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $10K · 2021: $2,196 · 2022: $4,413 · 2023: $427 · 2024: $399 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662 · Consulting Fee: $175 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.91 |
| Consulting Fee | $175.00 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $21,885.50 | 2019-2021 | |
| Mannkind Corporation | $4,090.57 | 2020-2023 | Afrezza |
| Sanofi US Services INC. | $325.00 | 2021 | |
| Novo Nordisk INC | $304.32 | 2019-2024 | Rybelsus, Wegovy |
| Abbott Laboratories | $267.89 | 2020-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $251.33 | 2023-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $236.16 | 2022-2025 | Omnipod |
| Lilly USA, LLC | $195.65 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Beta Bionics, INC. | $186.11 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Genzyme Corporation | $180.00 | 2019 | |
| Amgen INC. | $175.00 | 2025 | Prolia |
| Madrigal Pharmaceuticals | $159.92 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $153.28 | 2023-2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $147.00 | 2022 | |
| Radius Health, INC. | $115.08 | 2022-2024 | Tymlos |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $107.26 | 2024 | Crysvita |
| Sanofi-Aventis U.S. LLC | $102.53 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $48.20 | 2022-2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $40.70 | 2019 | |
| Sequel Med Tech, LLC | $34.47 | 2025 | Twiist |
| Medtronic, INC. | $31.76 | 2023-2025 | Minimed 780g |
| Medtronic Minimed, INC. | $23.29 | 2020 | |
| Ascensia Diabetes Care US INC. | $18.93 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.70 | 2024 | |
| Tandem Diabetes Care, INC. | $15.14 | 2022 | |
| Acella Pharmaceuticals, LLC | $14.29 | 2023 | NP Thyroid 60 |
| Cequr Corporation | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Solum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.